Anti-Mouse Ly6G Antibody – Purified in vivo GOLD™ Functional Grade

Anti-Mouse Ly6G Antibody – Purified in vivo GOLD™ Functional Grade

Product No.: L280

[product_table name="All Top" skus="L280"]

- -
- -
Clone
1A8
Target
Ly-6G
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Lymphocyte antigen 6 complex, locus G
Isotype
Rat IgG2a κ
Applications
CyTOF®
,
Depletion
,
FC
,
IHC FF
,
in vivo
,
PhenoCycler®
,
WB

- -
- -
Select Product Size

Data

Anti-Mouse Ly6G CyTOF™ Data
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Mouse Ly-6G transfected EL-4J cell line
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this Ly6G antibody (clone 1a8) for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
CyTOF®
Depletion
IHC (Frozen)
IHC (Paraffin)
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Ly6G antibody (clone 1A8) recognizes an epitope on mouse Ly6G. Clone 1A8 does not cross react with Ly6C.
Background
Ly6G antibody (clone 1A8) recognizes lymphocyte antigen 6 complex locus G6D (Ly6G; also called Gr-1), a 21-25 kDa glycosylphosphatidylinositol (GPI)-anchored protein1. Ly6G belongs to the lymphocyte antigen-6 (Ly6)/urokinase-type plasminogen activator receptor (uPAR) superfamily, characterized by a Ly6/uPAR (LU) domain-containing a three-fingered structural motif stabilized by disulfide bonds2. Ly6G is expressed by murine neutrophils regardless of location and activation1,4,5. Eosinophils may also express low levels of Ly6G5. There is no human ortholog for Ly6G; however, a structurally related L76/uPAR protein, CD177 (also known as HNA-2a, NB1, or PRV-1) is expressed in human neutrophils and is implicated in neutropenia6. Although the exact function and ligand of Ly6G remain unknown, Ly6G ligation may impair neutrophil migration to sites of inflammation via a β2-integrin-dependent mechanism7.
Antigen Distribution
Ly6G is expressed by neutrophils.
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

References & Citations

1. Fleming TJ, et al. (1993) J Immunol. 151(5):2399-408
2. Tsetlin VI. et al. (2015) Trends Pharmacol Sci. 36(2):109-23
3. Daley JM, et al. (2008) J Leukoc Biol. 83(1):64-70
4. Lee PY, et al. (2013) J Leukoc Biol. 94(4):585-594
5. Percopo CM, et al. (2017) J Leukoc Biol. 101(1):321-328.
6. Stroncek DF. et al. (2007) Curr Opin Hematol. 14(6):688-93
7. Wang JX, et al. (2012) Blood. 120(7):1489-1498
8. Gubin, M. et al. (2018) Cell. 175(4):1014–1030.e19 Journal Link
9. Lebratti, T.et al. (2021) eLife 10: e65762 Journal Link
10. 1. Tzetzo, S. L., Kramer, E. D., Mohammadpour, H., Kim, M., Rosario, S. R., Yu, H., Dolan, M., Oturkar, C. C., Morreale, B., Bogner, P. N., Stablewski, A., Benavides, F., Brackett, C. M., Ebos, J. M., Das, G. M., Opyrchal, M., Nemeth, M. J., Evans, S. S., & Abrams, S. I. (2024). Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. iScience, 109187. https://doi.org/10.1016/j.isci.2024.109187
CyTOF®
Depletion
Flow Cytometry
IHC FF
in vivo Protocol
PhenoCycler®
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.